JP2001518304A5 - - Google Patents

Download PDF

Info

Publication number
JP2001518304A5
JP2001518304A5 JP2000513958A JP2000513958A JP2001518304A5 JP 2001518304 A5 JP2001518304 A5 JP 2001518304A5 JP 2000513958 A JP2000513958 A JP 2000513958A JP 2000513958 A JP2000513958 A JP 2000513958A JP 2001518304 A5 JP2001518304 A5 JP 2001518304A5
Authority
JP
Japan
Prior art keywords
seq
multifunctional protein
interferon
group
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000513958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001518304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/020464 external-priority patent/WO1999016889A1/en
Publication of JP2001518304A publication Critical patent/JP2001518304A/ja
Publication of JP2001518304A5 publication Critical patent/JP2001518304A5/ja
Withdrawn legal-status Critical Current

Links

JP2000513958A 1997-10-01 1998-09-30 アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用 Withdrawn JP2001518304A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6060997P 1997-10-01 1997-10-01
US60/060,609 1997-10-01
PCT/US1998/020464 WO1999016889A1 (en) 1997-10-01 1998-09-30 Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment

Publications (2)

Publication Number Publication Date
JP2001518304A JP2001518304A (ja) 2001-10-16
JP2001518304A5 true JP2001518304A5 (enExample) 2006-01-05

Family

ID=22030604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000513958A Withdrawn JP2001518304A (ja) 1997-10-01 1998-09-30 アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用

Country Status (5)

Country Link
EP (2) EP1705248A1 (enExample)
JP (1) JP2001518304A (enExample)
AU (1) AU9673998A (enExample)
CA (1) CA2303401A1 (enExample)
WO (1) WO1999016889A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2313705A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Restin and methods of use thereof
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
WO1999061464A1 (en) * 1998-05-28 1999-12-02 Korea Green Cross Corporation Process of purifying angiogenesis inhibitors
JP2002530273A (ja) * 1998-07-13 2002-09-17 パーカシュ エス． ギル， 脈管形成および腫瘍増殖の新規インヒビター
WO2000054813A2 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU2004240199B2 (en) * 1999-04-30 2007-05-17 Novartis Vaccines And Diagnostics S.R.L. Conserved Neisserial antigens
WO2001060351A2 (en) * 2000-02-18 2001-08-23 New York Medical College Nitroacridine/tumor inhibitor compositions
CA2421251A1 (en) 2000-09-05 2002-03-14 Karolinska Innovations Ab Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
US7420036B2 (en) 2000-11-28 2008-09-02 Waisman David M Anti-angiogenic polypeptides
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US7893033B2 (en) 2002-05-06 2011-02-22 Board Of Regents, The University Of Texas System Targeting proteins to deliver therapeutic or diagnostic reagents
JP4511108B2 (ja) * 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
AU2003297181A1 (en) 2002-12-13 2004-07-09 Mediomics, Llc Compositions and methods for inhibiting tumor growth and metastasis
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
EP2628748A1 (en) 2012-02-14 2013-08-21 Szilak Laboratories Bioinformatics & Molecule-Design Ltd. Angiostatin chimeras and uses thereof
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
WO2014180288A1 (zh) * 2013-05-06 2014-11-13 中国药科大学 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
JP6689249B2 (ja) 2014-03-17 2020-05-20 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 錐体細胞における増強された遺伝子発現のための組成物および方法
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
AU2016226289B2 (en) 2015-03-02 2021-04-29 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CN114058636A (zh) * 2021-11-16 2022-02-18 大连润生康泰医学检验实验室有限公司 一种转甲状腺素蛋白基因的克隆、表达与纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
EP0297882B1 (en) * 1987-07-01 1993-08-25 Beecham Group Plc Hybrid plasminogen activators
CA2106079C (en) * 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
WO1995029242A1 (en) * 1994-04-26 1995-11-02 The Children's Medical Center Corporation Angiostatin and method of use for inhibition of angiogenesis
MX9708217A (es) * 1995-04-26 1997-12-31 Childrens Medical Center Fragmentos de angiostatina y angiostatina agregada y metodos de uso.
US5824299A (en) * 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
ES2206602T3 (es) * 1995-10-23 2004-05-16 The Children's Medical Center Corporation Compuestos y metodos terapeuticos inhibidores de angiogenesis.
US5837680A (en) * 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
ES2342239T3 (es) * 1998-08-25 2010-07-02 Merck Patent Gmbh Expresion y exportacion de angiostatina y de endostatina como inmunofusinas.

Similar Documents

Publication Publication Date Title
JP2001518304A5 (enExample)
JP2557053B2 (ja) 腫瘍壊死因子の精製、製造および使用法
EP0211148B2 (en) Mature human leukozyte interferons, process for their bacterial production, intermediates therefor and compositions containing them
CN102212019B (zh) 支化水溶性聚合物及其缀合物
US6187751B1 (en) Biologically active peptide of ob protein
EP0051873A2 (en) Hybrid human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them
JP2002528060A5 (enExample)
JP2004531242A5 (enExample)
CA2641565A1 (en) Nel-related proteins type 1 and 2, and polynucleotides encoding them
HU202921B (en) Process for producing coding dns for human tumor necrosis factor the corresponding polypeptide with utilizing them and pharmaceutical compositions containing this polypeptide as active component
JP2004536077A5 (enExample)
KR20000016402A (ko) 렙틴(ob단백질)의 프레그먼트
CA2311648A1 (en) Ifnar2/ifn complex
Van Poelje et al. Cloning, sequencing, expression, and site-directed mutagenesis of the gene from Clostridium perfringens encoding pyruvoyl-dependent histidine decarboxylase
EP0534568B1 (en) Human growth hormone analogues and their use
PT96224A (pt) Producao de factor de crescimento derivado de plaquetas biologicamente activas a partir de sistema de celulas hospedeiras de elevada expressao
JP2004533846A5 (enExample)
RU2005101076A (ru) Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации
CN101735200B (zh) 喹唑啉类化合物
JP2008502323A5 (enExample)
JP2009507474A5 (enExample)
CA2465667A1 (en) New peptides - analogs of human growth hormone-releasing hormone
JPWO2022204093A5 (enExample)
CN102949731A (zh) 与glp-2受体特异性结合的药物融合体
JPH01296996A (ja) 新規ペプチド